Loading...
Market
What will be the outcome of the Abbott Similac preterm infant formula trial by end of 2024?
2
Resolution / Starting Odds
Abbott found liable • 25%
Abbott not found liable • 25%
Mistrial declared • 25%
Case dismissed • 25%
Court verdict or official court documents
Story
Abbott Faces Trial on July 8 Over Claims Similac Preterm Infant Formula Causes Dangerous Disease
Jul 8, 2024, 10:11 AM
Abbott, the maker of Similac baby formula, is set to face a trial on Monday, July 8, over allegations that its specialty formula for preterm infants causes a serious intestinal disease. This trial marks the second in a series of hundreds of similar lawsuits in the United States. The formula is used in neonatal intensive care units and is accused of causing a potentially deadly bowel disease. The case has seen nutrition companies and parents clash in court over the cause of the disease.
View original story
Similar markets
Yes • 50%
No • 50%
Product recall • 25%
Product reformulation • 25%
No changes • 25%
Other • 25%
Yes • 50%
No • 50%
Verdict upheld • 25%
Verdict overturned • 25%
Settlement reached • 25%
Other • 25%
Yes • 50%
No • 50%
Successful with expected results • 25%
Partially successful • 25%
Unsuccessful • 25%
Results inconclusive • 25%
Settlement • 33%
Dismissal • 33%
Trial • 33%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
All rejected • 33%
Some accepted, some rejected • 33%
All accepted • 33%
Settlement reached • 25%
Trial verdict in favor of plaintiffs • 25%
Trial verdict in favor of Johnson & Johnson • 25%
Ongoing litigation • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%